🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

11,276 results for “Te” Clear

  1. JNJ-77242113-AAC Placebo tablet, JNJ-77242113

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  2. JNJ-78278343, Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, JNJ-78278343, Prednison acis 5 mg, Tabletten, DOCETAXEL , PREDNISONE

    Janssen-Cilag International N.V.

    Metastatic Castration-resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  3. JNJ-80202135, Placebo subcutaneous without Nipocalimab

    Janssen-Cilag International N.V.

    Sjögren's Disease

    phase 3 small molecule active

    1 trial

  4. JNJ-80202135, Placebo subcutaneous without Nipocalimab

    Janssen-Cilag International N.V.

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  5. JNT-517 Placebo, JNT-517, JNT-517

    Otsuka Beijing Research Institute

    Phenylketonuria

    phase 3 small molecule active

    1 trial

  6. JPB898 (Induction and Maintenance)

    Sandoz Pty Ltd

    Melanoma

    phase 3 small molecule terminated

    1 trial

  7. JR-141

    Lacuna Pharma Pty Ltd

    Mucopolysaccharidosis type II, Hunter Syndrome

    phase 3 small molecule active

    1 trial

  8. JR-141, Elaprase 2 mg/ml concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Mucopolysaccharidosis type II, Hunter Syndrome

    phase 3 small molecule active

    1 trial

  9. JX10, Jx10 placebo drug product is prepared as a sterile, lyophilized white to light yellow cake or powder for infusion.

    Lacuna Pharma Pty Ltd

    Acute ischemic stroke

    phase 3 small molecule active

    1 trial

  10. JZP-110

    Jazz Pharmaceuticals Ireland Limited

    Narcolepsy

    phase 3 small molecule completed

    3 trials

  11. JZP-110

    Jazz Pharmaceuticals Ireland Limited

    Obstructive Sleep Apnea

    phase 3 small molecule completed

    3 trials

  12. JZP-258

    Jazz Pharmaceuticals Ireland Limited

    Narcolepsy With Cataplexy

    phase 3 small molecule completed

    1 trial

  13. JZP-258

    Jazz Pharmaceuticals Ireland Limited

    Idiopathic Hypersomnia

    phase 3 small molecule completed

    1 trial

  14. JZP598, GEMCITABINE , TRASTUZUMAB , CAPECITABINE , VINORELBINE , ERIBULIN

    Jazz Pharmaceuticals Ireland Limited

    Metastatic HER2-positive breast cancer

    phase 3 small molecule active

    1 trial

  15. Japanese encephalitis vaccine

    Sanofi Pasteur

    Japanese Encephalitis

    phase 3 mab completed

    1 trial

  16. Jardiance 10 mg film-coated tablets, Placebo matching vicadrostat, BI 690517

    Boehringer Ingelheim

    Type 2 diabetes, hypertension, cardiovascular disease

    phase 3 small molecule active

    1 trial

  17. Jardiance 10 mg film-coated tablets, empagliflozin, Placebo matching empagliflozin, film-coated tablets

    Boehringer Ingelheim

    Chronic kidney disease in paediatric patients

    phase 3 small molecule active

    1 trial

  18. Jaypirca 100 mg film-coated tablets, BGB-16673, BGB-16673

    BEONE MEDICINES AUS PTY LTD

    Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL)

    phase 3 small molecule active

    1 trial

  19. Jinarc 30 mg tablets, Tolvaptan, Jinarc 15 mg tablets, Samsca 7.5 mg tablets

    Otsuka Beijing Research Institute

    Autosomal Recessive Polycystic Kidney Disease

    phase 3 small molecule active

    1 trial

  20. Juanbi pill

    Universal Integrated

    Juanbi Pill

    phase 3 small molecule active

    1 trial

  21. Jyseleca 100 mg film-coated tablets, Jyseleca 200 mg film-coated tablets

    Alfasigma S.p.A.

    Rheumatoid arthritis

    phase 3 small molecule active

    1 trial

  22. Jyseleca 100 mg film-coated tablets, Jyseleca 200 mg film-coated tablets, Composition apart from the active substance otherwise to identical to IMP

    Alfasigma S.p.A.

    Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  23. Jyseleca 200 mg film-coated tablets, Jyseleca 100 mg film-coated tablets, GLPG0634

    Alfasigma S.p.A.

    Polyarticular-course juvenile idiopathic arthritis

    phase 3 small molecule active

    1 trial

  24. KAI-9531

    Kailera Therapeutics

    Obesity With Diabetes

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources